Alector (ALEC) Q2 2024 earnings summary

Executive summary

• Advanced clinical pipeline in neurodegenerative diseases with key programs: latozinemab (pivotal Phase 3 for FTD-GRN, FDA Breakthrough Therapy Designation), AL002 (Phase 2 for Alzheimer's with AbbVie), and AL101 (Phase 2 for Alzheimer's with GSK).

• Launched Alector Brain Carrier (ABC) platform to enhance blood-brain barrier drug delivery and expand preclinical and clinical capabilities.

• Collaborations with GSK and AbbVie provide significant funding and cost-sharing for clinical programs.

• Reported Q2 2024 net loss of $38.7M and accumulated deficit of $784.8M as of June 30, 2024.

• Cash, cash equivalents, and marketable securities totaled $503.3M as of June 30, 2024, expected to fund operations through 2026.

Financial highlights

• Q2 2024 collaboration revenue was $15.1M, down from $56.2M in Q2 2023, mainly due to lower AL101 and AL002 program revenue.

• R&D expenses were $46.3M in Q2 2024, flat year-over-year; G&A expenses rose to $14.4M.

• Net loss per share was $(0.40) for Q2 2024, compared to $0.02 earnings per share in Q2 2023.

• 2024 collaboration revenue guidance: $60–$70M; R&D expense guidance: $210–$220M; G&A expense guidance: $60–$70M.

• Cash and marketable securities decreased to $503.3M from $548.9M at year-end 2023.

Outlook and guidance

• Cash runway expected to fund operations through 2026 and beyond key clinical milestones.

• AL002 INVOKE-2 Phase 2 data readout expected in Q4 2024; pivotal INFRONT-3 Phase 3 data for latozinemab anticipated late 2025/early 2026.

• AbbVie opt-in decision for AL002 expected within 90 days after Phase 2 data package submission, likely by Q1/Q2 2025.

• The company anticipates continued net losses and may seek additional capital through equity, debt, or collaborations.